↓ Skip to main content

Dove Medical Press

Article Metrics

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Overview of attention for article published in Drug Design, Development and Therapy, May 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
20 Mendeley
Title
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Published in
Drug Design, Development and Therapy, May 2017
DOI 10.2147/dddt.s130909
Pubmed ID
Authors

Maria Victoria Borrás Pérez, Berit Kriström, Tomasz Romer, Mieczyslaw Walczak, Nadja Höbel, Markus Zabransky

Abstract

Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope(®) (biosimilar rhGH) was approved by the European Medicines Agency in 2006, with approval granted on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®)). Additional concerns that may exist in relation to biosimilar rhGH include safety in indications granted on the basis of extrapolation and the impact of changing to biosimilar rhGH from other rhGH treatments. A substantial data set is available to fully understand the safety profile of biosimilar rhGH, which includes data from its clinical development studies and 10 years of post-approval experience. As of June 2016, 106,941,419 patient days (292,790 patient-years) experience has been gathered for biosimilar rhGH. Based on the available data, there have been no unexpected or unique adverse events related to biosimilar rhGH treatment. There is no increased risk of cancer, adverse glucose homeostasis, or immunogenic response with biosimilar rhGH compared with the reference medicine and other rhGH products. The immunogenicity of biosimilar rhGH is also similar to that of the reference and other rhGH products. Physicians should be reassured that rhGH products have a good safety record when used for approved indications and at recommended doses, and that the safety profile of biosimilar rhGH is in keeping with that of other rhGH products.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 30%
Student > Master 4 20%
Other 2 10%
Professor 2 10%
Librarian 1 5%
Other 2 10%
Unknown 3 15%
Readers by discipline Count As %
Medicine and Dentistry 6 30%
Pharmacology, Toxicology and Pharmaceutical Science 4 20%
Biochemistry, Genetics and Molecular Biology 2 10%
Nursing and Health Professions 1 5%
Computer Science 1 5%
Other 3 15%
Unknown 3 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2017.
All research outputs
#3,907,962
of 13,600,257 outputs
Outputs from Drug Design, Development and Therapy
#214
of 1,417 outputs
Outputs of similar age
#89,153
of 263,354 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 38 outputs
Altmetric has tracked 13,600,257 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,417 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.